<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00145704</url>
  </required_header>
  <id_info>
    <org_study_id>SUNY UMU IRB # 4689</org_study_id>
    <nct_id>NCT00145704</nct_id>
  </id_info>
  <brief_title>Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density</brief_title>
  <official_title>Treatment of Childhood Cancer Therapy-induced Osteopenia in Growth Hormone Deficient Adult Survivors: Does Bisphosphonate Treatment Improve Bone Mineral Density?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Upstate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York - Upstate Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to evaluate the hypothesis that bisphosphonate treatment given
      to growth hormone deficient patients (regardless of current growth hormone replacement
      therapy status and without changing that status) significantly increases total body bone
      mineral density during an eighteen month period of treatment combined with calcium and
      Vitamin D when compared to calcium and Vitamin D treatment alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with Dexa scan (bone scan) z-scores &lt; -1.0 (meaning low bone density) in at
      least one site will be selected for randomization. All patients who qualify for randomization
      will undergo baseline bloodwork for serum bone specific alkaline phosphatase (BSAP) and
      n-terminal telopeptides of collagen (NTX) levels. Recent bloodwork obtained as part of their
      ongoing long-term Pediatric Oncology and/or Endocrine clinic follow-up evaluation will be
      reviewed to exclude any baseline correctable confounding causes of osteopenia (low bone
      density). All women of childbearing potential will have a pregnancy test.

      For those patients already on growth hormone replacement therapy, growth hormone will be
      administered as per standard of care, with standard dose ranges adjusted based upon
      IGF-1(Insulin like growth factor) monitoring. Those patients not currently receiving growth
      hormone replacement therapy will not be placed on therapy as a part of this study. Patients
      on and off growth hormone replacement therapy will be randomized in a block design to the two
      treatment arms to assure equal numbers in each treatment arm. The bisphosphonate to be
      utilized will be provided to the Arm II patients at no charge. All Arm II patients will
      receive the same bisphosphonate regimen, Risedronate 35 mg per oral once weekly for 18
      months. All patients on arms I and II will also receive Vitamin D (400 IU p.o. daily) and
      calcium carbonate (500 mg p.o. twice daily) free of charge for eighteen months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to low enrollment, participants are no longer being examined or treated
  </why_stopped>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Body Bone Mineral Density During an 18 Month Period</measure>
    <time_frame>18 months</time_frame>
    <description>For those patients already on growth hormone replacement therapy, growth hormone will be administered as per standard of care, with standard dose ranges adjusted based upon IGF-1 monitoring. Those patients not currently receiving growth hormone replacement therapy will not be placed on therapy as a part of this study. Patients on and off growth hormone replacement therapy will be randomized in a block design to the two treatment arms to assure equal numbers in each treatment arm. The bisphosphonate to be utilized will be provided to the Arm II patients at no charge. All Arm II patients will receive the same bisphosphonate regimen, Risedronate 35 mg per oral once weekly for 18 months. All patients on arms I and II will also receive Vitamin D (400 IU p.o. daily) and calcium carbonate (500 mg p.o. twice daily) free of charge for eighteen months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Growth Hormone only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No bisphosphonate therapy given, participants will take Vitamin D 400 IU daily for 18 months, as well as calcium carbonate 500 mg twice a day for 18 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Growth Hormone &amp; Bisphosphonate Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bisphosphonate Therapy-Risedronate 35 mg once a week for 18 months, Vitamin D 400 IU daily for 18 months and calcium carbonate 500 mg twice daily for 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bisphosphonate therapy (risedronate)</intervention_name>
    <description>Bisphosphonate therapy given to patients with growth hormone deficiency</description>
    <arm_group_label>Growth Hormone &amp; Bisphosphonate Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D supplement</intervention_name>
    <description>Vitamin D given to patients with growth hormone deficiency</description>
    <arm_group_label>Growth Hormone only</arm_group_label>
    <arm_group_label>Growth Hormone &amp; Bisphosphonate Therapy</arm_group_label>
    <other_name>Over the counter Vitamin D 400 IU.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium</intervention_name>
    <description>calcium supplement given to patients with growth hormone deficiency</description>
    <arm_group_label>Growth Hormone only</arm_group_label>
    <arm_group_label>Growth Hormone &amp; Bisphosphonate Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Growth hormone deficiency as a complication of treatment for pediatric malignancy

          -  Dexa (bone densitometry)with z-scores of &lt; -1.0 in at least one site

        Exclusion Criteria:

          -  Dexa (bone densitometry)with z-scores &lt; -1.0 in at least one site

          -  Subjects &lt;18 years old

          -  Pregnant or lactating patients

          -  Any contraindication for or unwillingness to consider bisphosphonate treatment

          -  Inability or unwillingness to undergo bone density evaluation

          -  Other correctable causes of decreased bone mineral density
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy A Damron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York - Upstate Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <results_first_submitted>October 26, 2010</results_first_submitted>
  <results_first_submitted_qc>March 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 8, 2013</results_first_posted>
  <last_update_submitted>March 1, 2013</last_update_submitted>
  <last_update_submitted_qc>March 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York - Upstate Medical University</investigator_affiliation>
    <investigator_full_name>Timothy Damron, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>osteopenia</keyword>
  <keyword>growth hormone deficiency</keyword>
  <keyword>pediatric malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult pts from Upstate Med Univ who have known growth hormone deficiency as a complication of treatment for pediatric malignancy will be selected after chart review from their Kids Not on Treatment(KNOT)Clinic records prior to their routine follow up appt.Pts will receive info about this study on their routine f/w up appts at the KNOT Clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bisphosphonate and Growth Hormone</title>
          <description>bisphosphonate use and growth hormone use</description>
        </group>
        <group group_id="P2">
          <title>Growth Hormone Only</title>
          <description>Growth hormone only, no bisphosphonate will be used</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bisphosphonate and Growth Hormone Use</title>
          <description>bisphosphonate use and growth hormone use</description>
        </group>
        <group group_id="B2">
          <title>Growth Hormone Only</title>
          <description>Growth hormone use only, no bisphosphonate used</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="18" upper_limit="40"/>
                    <measurement group_id="B2" value="25" lower_limit="18" upper_limit="40"/>
                    <measurement group_id="B3" value="25" lower_limit="18" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Body Bone Mineral Density During an 18 Month Period</title>
        <description>For those patients already on growth hormone replacement therapy, growth hormone will be administered as per standard of care, with standard dose ranges adjusted based upon IGF-1 monitoring. Those patients not currently receiving growth hormone replacement therapy will not be placed on therapy as a part of this study. Patients on and off growth hormone replacement therapy will be randomized in a block design to the two treatment arms to assure equal numbers in each treatment arm. The bisphosphonate to be utilized will be provided to the Arm II patients at no charge. All Arm II patients will receive the same bisphosphonate regimen, Risedronate 35 mg per oral once weekly for 18 months. All patients on arms I and II will also receive Vitamin D (400 IU p.o. daily) and calcium carbonate (500 mg p.o. twice daily) free of charge for eighteen months.</description>
        <time_frame>18 months</time_frame>
        <population>Data analyis halted, due to low enrollment,no outcomes to report</population>
        <group_list>
          <group group_id="O1">
            <title>Bisphosphonate and Growth Hormone Use</title>
            <description>bisphosphonate use and growth hormone use</description>
          </group>
          <group group_id="O2">
            <title>Growth Hormone Only</title>
            <description>Growth hormone use only, no bisphosphonate used</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Body Bone Mineral Density During an 18 Month Period</title>
          <description>For those patients already on growth hormone replacement therapy, growth hormone will be administered as per standard of care, with standard dose ranges adjusted based upon IGF-1 monitoring. Those patients not currently receiving growth hormone replacement therapy will not be placed on therapy as a part of this study. Patients on and off growth hormone replacement therapy will be randomized in a block design to the two treatment arms to assure equal numbers in each treatment arm. The bisphosphonate to be utilized will be provided to the Arm II patients at no charge. All Arm II patients will receive the same bisphosphonate regimen, Risedronate 35 mg per oral once weekly for 18 months. All patients on arms I and II will also receive Vitamin D (400 IU p.o. daily) and calcium carbonate (500 mg p.o. twice daily) free of charge for eighteen months.</description>
          <population>Data analyis halted, due to low enrollment,no outcomes to report</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>May, 2002 to October 2008</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bisphosphonate and Growth Hormone Use</title>
          <description>bisphosphonate use and growth hormone use</description>
        </group>
        <group group_id="E2">
          <title>Growth Hormone Only</title>
          <description>Growth hormone use only, no bisphosphonate used</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to low enrollment, and lost to follow up of three subjects. Data was limited and therefore not reviewed/analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Timothy A. Damron</name_or_title>
      <organization>Upstate Orthopedics</organization>
      <phone>315-464-8602</phone>
      <email>damront@upstate.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

